Company Continues its Expansion into the Healthcare Professional Market through One-on-One Education, Exclusive Product Offerings and Enhanced Practitioner Support.
LAS VEGAS, April 18, 2018 -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company," "CV Sciences," "our" or "we"), preeminent manufacturer and distributor of the industry-dominating brand of hemp extract products, PlusCBD Oil™, announced today that it will be exhibiting at the 15th Annual Nutrition and Health Conference, held on April 29th to May 2nd, 2018 at the Westin Boston Waterfront in Boston, MA as a Silver Level Sponsor.
The Nutrition and Health Conference, produced by the Arizona Center for Integrative Medicine, is a continuing education conference that assembles internationally recognized researchers, clinicians, educators, and chefs whose work focuses on the interface between nutrition and healthful living. The conference will feature presentations and a lively panel discussion with renowned health expert Dr. Andrew Weil and nationally renowned nutrition experts discussing optimum diet and social and political issues related to food and nutrition.
Exhibiting brands are chosen based on philosophical fit of the organization’s values and mission, as well as representing quality products that serve the health and wellness of their attendees and patients. “We are thrilled to be the first hemp CBD company to sponsor and exhibit at the Nutrition and Health Conference,” stated Stuart Tomc, VP of Human Nutrition at CV Sciences. “Conference leadership has set a strict standard to ensure high-quality dietary supplements and foods are represented to their attendees, and we look forward to educating forward-thinking practitioners on the value hemp CBD products like PlusCBD Oil™ may offer their clients and patients.”
VISIT THE CV SCIENCES TABLE: CV Sciences invites attendees to visit the CV Sciences table to learn more about their botanical-based CBD product line, PlusCBD Oil™. The Company will additionally feature its brand of practitioner-exclusive products available only to healthcare providers nationwide. Also, CV Sciences will be offering exclusive trade show discounts and show specials to practitioners attending the show.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
CONTACT:
Robert Haag, Managing Director
IRTH Communications
[email protected]
866-976-4784


Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims
FTC Questions Apple News Over Alleged Bias Against Conservative Media
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy
Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 



